With multiple PARPi + ARSI combinations now approved, how are you selecting which combination to use for a patient with BRCA mutated mCRPC?

Topics: Genitourinary Cancers • Prostate Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Duke • NCI-CCC GU Tumor Board Question • Duke GU Tumor Board

Answer from: Medical Oncologist at Academic Institution

As of this writing, we have 3 choices for a man with mCRPC and a BRCA2 mutation who has never had a prior ARSI and is now progressing on ADT with or without docetaxel in the mHSPC setting or ADT in the nmCRPc setting. Abiraterone plus olaparib has the longest follow up and a clearly significant over...

Comments

Medical Oncologist at University of Minnesota–Masonic Cancer Center
I agree with Dr. @Armstrong. Figure 1 in the attac...

Related Questions